The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Lilly; Merck; Novartis; Sanofi
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Yoon-Koo Kang
Consulting or Advisory Role - Bristol-Myers Squibb; DAEHWA Pharmaceutical; Lilly/ImClone; Merck Serono; Ono Pharmaceutical; Roche/Genentech; Taiho Pharmaceutical
Research Funding - DAEHWA Pharmaceutical; LSK Biopharma
 
Chia-Jui Yen
No Relationships to Disclose
 
Richard S. Finn
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Peter R. Galle
Honoraria - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Sirtex Medical
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly
Speakers' Bureau - Bayer; Sirtex Medical
Research Funding - Bayer
Travel, Accommodations, Expenses - Bayer
 
Josep M. Llovet
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celsion; Eisai; Exelixis; Glycotest; Incyte; Lilly
Research Funding - Bayer Schering Pharma (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst)
Travel, Accommodations, Expenses - Bayer
 
Eric Assenat
Honoraria - Bayer; Novartis; Sirtex Medical
Consulting or Advisory Role - Ipsen; Sanofi
Travel, Accommodations, Expenses - Bayer; Ipsen
 
Giovanni Brandi
No Relationships to Disclose
 
Ho Yeong Lim
No Relationships to Disclose
 
Marc Pracht
No Relationships to Disclose
 
Kun-Ming Rau
No Relationships to Disclose
 
Philippe Merle
No Relationships to Disclose
 
Kenta Motomura
No Relationships to Disclose
 
Izumi Ohno
Consulting or Advisory Role - Merck Serono
Speakers' Bureau - Taiho Pharmaceutical
 
Bruno Daniele
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Lilly; Merck KGaA; MSD
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Merck KGaA
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb
 
Dongbok Shin
No Relationships to Disclose
 
Guido Gerken
No Relationships to Disclose
 
Paolo Abada
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Yanzhi Hsu
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Lilly
 
Masatoshi Kudo
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Gilead Sciences; Merck Serono; Merck Serono; MSD; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; MSD
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)